Celldex Therapeutics reported $317.69M in Current Assets for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Assets Change
Agenus AGEN:US USD 213.12M 38.31M
Amgen AMGN:US USD 22.19B 1.88B
Aptinyx Inc APTX:US USD 73.95M 18.19M
Biocept BIOC:US USD 36.64M 7.14M
Celldex Therapeutics CLDX:US USD 317.69M 16.91M
Cytrx CYTR:US USD 6.18M 2.1M
Glaxosmithkline GSK:US GBP 20.77B 520M
Immunogen IMGN:US USD 304.12M 26.3M
Merrimack Pharmaceuticals MACK:US USD 13.63M 417K
Nektar Therapeutics NKTR:US USD 545.97M 53.52M
Newlink Genetics NLNK:US USD 72.01M 6.82M
Northwest Biotherapeutics NWBO:US USD 11.76M 4.59M
Rigel Pharmaceuticals RIGL:US USD 115.9M 5.46M
Roche Holding ROG:VX 33.82B 3.5B
Seattle Genetics SGEN:US USD 2.8B 42.91M